Venturi Wealth Management LLC Buys Shares of 1,074 Medpace Holdings, Inc. $MEDP

Key Points

• Venturi Wealth Management LLC has purchased 1,074 shares of Medpace Holdings, Inc., valued at approximately $337,000, marking a new investment during the second quarter.
• Multiple institutional investors, including Whittier Trust Co. and Benjamin Edwards Inc., have increased their holdings in Medpace, reflecting a strong institutional interest with 77.98% of shares owned by such investors.
• Medpace reported a quarterly earnings per share (EPS) of $3.10, surpassing estimates and reflecting a year-over-year revenue growth of 14.2%; analysts predict an EPS of 12.29 for the current fiscal year.

Venturi Wealth Management LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,074 shares of the company's stock, valued at approximately $337,000.

A number of other institutional investors also recently bought and sold shares of the company. Whittier Trust Co. lifted its holdings in Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after acquiring an additional 35 shares during the period. Benjamin Edwards Inc. increased its position in Medpace by 3.1% in the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock worth $366,000 after buying an additional 36 shares in the last quarter. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after buying an additional 37 shares in the last quarter. Assetmark Inc. increased its position in Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after buying an additional 43 shares in the last quarter. Finally, Sheets Smith Wealth Management increased its position in Medpace by 1.3% in the second quarter. Sheets Smith Wealth Management now owns 3,332 shares of the company's stock worth $1,046,000 after buying an additional 43 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Insiders Place Their Bets

In related news, VP Susan E. Burwig sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the completion of the sale, the vice president directly owned 57,500 shares of the company's stock, valued at approximately $27,600,000. This trade represents a 14.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares of the company's stock, valued at $4,654,350. This represents a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 161,266 shares of company stock worth $74,111,427. 20.30% of the stock is currently owned by company insiders.

Medpace Price Performance

NASDAQ:MEDP opened at $501.22 on Friday. The firm has a market capitalization of $14.08 billion, a price-to-earnings ratio of 37.27, a PEG ratio of 3.26 and a beta of 1.40. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $547.15. The business has a 50 day simple moving average of $483.32 and a 200-day simple moving average of $374.53.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.10. The business had revenue of $603.31 million during the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company's revenue for the quarter was up 14.2% on a year-over-year basis. During the same period last year, the company earned $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on MEDP. Deutsche Bank Aktiengesellschaft upped their price target on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Weiss Ratings restated a "buy (b-)" rating on shares of Medpace in a research report on Wednesday. TD Cowen restated a "sell" rating and issued a $366.00 price target (up previously from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Zacks Research cut Medpace from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 22nd. Finally, William Blair reissued a "market perform" rating on shares of Medpace in a research note on Wednesday, July 23rd. Three investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of "Hold" and an average price target of $422.27.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.